Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Rheumatology: Biosimilars are here to stay

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre international cohort, with particular focus on unresolved issues, including scleroderma renal crisis (RC), malignancies, and functional outcome of interstitial lung disease (ILD).

METHODS: (1) Analysis of SSc patients from the EUSTAR database: 144 anti-PM/Scl+ without SSc-specific autoantibodies were compared with 7202 anti-PM/Scl-, and then to 155 anti-Pm/Scl+ with SSc-specific antibodies. (2) Case-control study: additional data were collected for 165 anti-PM/Scl+ SSc patients (85 from the EUSTAR registry) and compared with 257 anti-PM/Scl- SSc controls, matched for sex, cutaneous subset, disease duration and age at SSc onset.

RESULTS: Patients with isolated anti-PM/Scl+, as compared with anti-Pm/Scl-, had higher frequency of muscle involvement, ILD, calcinosis and cutaneous signs of DM, but similar frequency of SRC and malignancies (either synchronous with SSc onset or not). The presence of muscle involvement was associated with a more severe disease phenotype. Although very frequent, ILD had a better functional outcome in cases than in controls. In patients with both anti-PM/Scl and SSc-specific antibodies, a higher frequency of typical SSc features than in those with isolated anti-PM/Scl was observed.

CONCLUSION: The analysis of the largest series of anti-PM/Scl+ SSc patients so far reported helps to delineate a specific clinical subset with muscle involvement, cutaneous DM, calcinosis and ILD characterized by a good functional outcome. SRC and malignancies do not seem to be part of this syndrome.

Original languageEnglish
JournalRheumatology (Oxford, England)
Issue number11
Pages (from-to)5028-5041
Number of pages14
Publication statusPublished - 3 Nov 2021

Bibliographical note

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email:

    Research areas

  • Adult, Autoantibodies, Europe/epidemiology, Exoribonucleases/immunology, Exosome Multienzyme Ribonuclease Complex/immunology, Female, Humans, Male, Middle Aged, Phenotype, Registries, Retrospective Studies, Scleroderma, Systemic/complications, biomarkers, scleroderma and related disorders, laboratory diagnosis, myositis and muscle disease, autoantigens and autoantibodies

ID: 70592385